Background COVID-19 has been an unprecedented pandemic resulting in high mortality.
We report our experience of using a treatment protocol in the intensive care unit (ICU) during …

1 Tuite AR, Ng V, Rees E, et al. Estimation of the COVID-19 burden in Egypt through
exported case detection. Lancet Infect Dis 2020; published online March 26. https://doi …

Objectives Molnupiravir and nirmatrelvir/ritonavir each became available in the United
States (US) through the Food and Drug Administration (FDA) emergency use authorization …

Cellular and humoral immunity against severe acute respiratory syndrome coronavirus
(SARS-CoV-2), either naturally acquired or vaccine-elicited, are both essential for limiting …

Background Effective antiviral drugs prevent hospitalisation and death from COVID-19.
Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 …

It has been recently suggested that prior exposure to seasonal coronaviruses might confer
cross-protection against SARS-CoV-2. 1 Whether SARS-CoV-2 infection itself confers …

Objectives To evaluate the efficacy and safety of molnupiravir for intra-household post-
exposure prophylaxis (PEP) of COVID-19. Methods MOVe-AHEAD was a randomized …

1 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–62. 2 …

Abstract 1 Background 2 We evaluated effectiveness of mRNA-based vaccines following
emergence of SARS-CoV-2 3 Omicron variant. 4 Methods 5 Recipients of a third dose of …

TO THE EDITOR—We read with great interest the article by Montejano and colleagues,
which aimed to assess how the inclusion criteria of ongoing phase 2 and 3 clinical trials for …